A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
PROGRESS
A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study in PatientS With Diabetic Peripheral Neuropathic Pain (PROGRESS)
2 other identifiers
interventional
496
1 country
108
Brief Summary
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Nov 2023
Shorter than P25 for phase_2
108 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 29, 2023
CompletedFirst Submitted
Initial submission to the registry
November 30, 2023
CompletedFirst Posted
Study publicly available on registry
January 12, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 14, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 24, 2025
CompletedOctober 10, 2025
October 1, 2025
1.1 years
November 30, 2023
October 8, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Change from Baseline to Week 8 in Average Daily Pain Score (ADPS)
ADPS is based on the 11-point numerical rating scale (NRS) \[0 (no pain) to 10 (worst imaginable pain)\].
Baseline, Week 8
Secondary Outcomes (4)
Change from Baseline to Week 8 in Burning Pain
Baseline, Week 8
Change from Baseline to Week 8 in Pain Interference on Sleep
Baseline, Week 8
Patient Global Impression of Change (PGIC) Score at Week 8
Week 8
Change from Baseline to Week 8 in Total Neuropathic Pain Symptom Inventory (NPSI) Score
Baseline, Week 8
Study Arms (4)
LX9211 Low Dose
EXPERIMENTALLX9211 low dose, orally, once daily during a blinded treatment period.
LX9211 High Dose
EXPERIMENTALLX9211 high dose, orally, once daily during a blinded treatment period.
LX9211 High Dose Followed by Low Dose
EXPERIMENTALLX9211 high dose followed by LX9211 low dose, orally, once daily during a blinded treatment period.
LX9211 Placebo
PLACEBO COMPARATORLX9211 matching placebo, orally, once daily during a blinded treatment period.
Interventions
LX9211 (blinded) tablets
Eligibility Criteria
You may qualify if:
- Participant has given written informed consent to participate in the study in accordance with local regulations
- Adult male and female participants ≥18 years of age at the Screening Visit
- Body mass index ≥18.0 to ≤40.0 kilogram per meter square (kg/m\^2) at Screening
- Diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) with chronic DPNP, at Screening
- Pain from DPNP present for at least 6 months prior to Screening
- At the Screening Visit, glycosylated hemoglobin (A1C) must be ≤11%.
- Stable regimen for the treatment of T1DM or T2DM for ≥3 months prior to Screening
- Willing to adhere to the prohibitions and restrictions specified in the protocol.
You may not qualify if:
- Presence of other painful conditions that may confound assessment or self-evaluation of DPNP
- History of neurolytic or neurosurgical therapy for DPNP
- Use of opioid medications for management of DPNP within the 2 months prior to the Screening Visit.
- Use of prescription topical analgesics (eg, capsaicin) indicated for neuropathic pain within 3 months prior to Screening
- Use of nonsteroidal anti-inflammatory drugs (NSAIDs) less than 2 weeks prior to Screening
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (108)
Lexicon Investigational Site (128)
Anniston, Alabama, 36207, United States
Lexicon Investigational Site (222)
Birmingham, Alabama, 35216, United States
Lexicon Investigational Site (189)
Daphne, Alabama, 36526, United States
Lexicon Investigational Site (215)
Guntersville, Alabama, 35976, United States
Lexicon Investigational Site (115)
Chandler, Arizona, 85286, United States
Lexicon Investigational Site (195)
Phoenix, Arizona, 85028, United States
Lexicon Investigational Site (206)
Scottsdale, Arizona, 85258, United States
Lexicon Investigational Site (102)
Tucson, Arizona, 85741, United States
Lexicon Investigational Site (107)
Anaheim, California, 92801, United States
Lexicon Investigational Site (173)
Canoga Park, California, 91303, United States
Lexicon Investigational Site (179)
Escondido, California, 92025, United States
Lexicon Investigational Site (161)
Fresno, California, 93710, United States
Lexicon Investigational Site (112)
Greenbrae, California, 94904, United States
Lexicon Investigational Site (204)
Huntington Beach, California, 92647, United States
Lexicon Investigational Site (191)
Inglewood, California, 90301, United States
Lexicon Investigational Site (163)
Lomita, California, 90717, United States
Lexicon Investigational Site (169)
Long Beach, California, 90806, United States
Lexicon Investigational Site (111)
Sacramento, California, 95821, United States
Lexicon Investigational Site (126)
Sacramento, California, 95821, United States
Lexicon Investigational Site (129)
San Diego, California, 92103, United States
Lexicon Investigational Site (154)
San Diego, California, 92120, United States
Lexicon Investigational Site (124)
Tustin, California, 92780, United States
Lexicon Investigational Site (211)
Vista, California, 92081, United States
Lexicon Investigational Site (171)
Walnut Creek, California, 94596, United States
Lexicon Investigational Site (181)
Walnut Creek, California, 94598, United States
Lexicon Investigational Site (119)
Brandon, Florida, 33511, United States
Lexicon Investigational Site (194)
Brandon, Florida, 33511, United States
Lexicon Investigational Site (177)
Daytona Beach, Florida, 32117, United States
Lexicon Investigational Site (198)
Fleming Island, Florida, 32003, United States
Lexicon Investigational Site (109)
Fort Myers, Florida, 33912, United States
Lexicon Investigational Site (180)
Hollywood, Florida, 33024, United States
Lexicon Investigational Site (188)
Jacksonville, Florida, 32256, United States
Lexicon Investigational Site (164)
Miami, Florida, 33176, United States
Lexicon Investigational Site (105)
New Port Richey, Florida, 34652, United States
Lexicon Investigational Site (146)
Orlando, Florida, 32801, United States
Lexicon Investigational Site (144)
Orlando, Florida, 32806, United States
Lexicon Investigational Site (123)
Ormond Beach, Florida, 32174, United States
Lexicon Investigational Site (182)
Plantation, Florida, 33317, United States
Lexicon Investigational Site (133)
The Villages, Florida, 32159, United States
Lexicon Investigational Site (138)
The Villages, Florida, 32162, United States
Lexicon Investigational Site (131)
Winter Haven, Florida, 33880, United States
Lexicon Investigational Site (103)
Winter Park, Florida, 32789, United States
Lexicon Investigational Site (150)
Atlanta, Georgia, 30303, United States
Lexicon Investigational Site (151)
Marietta, Georgia, 30060, United States
Lexicon Investigational Site (172)
Chicago, Illinois, 60623, United States
Lexicon Investigational Site (132)
Flossmoor, Illinois, 60422, United States
Lexicon Investigational Site (185)
El Dorado, Kansas, 67042, United States
Lexicon Investigational Site (178)
Newton, Kansas, 67114, United States
Lexicon Investigational Site (186)
Wichita, Kansas, 67207, United States
Lexicon Investigational Site (213)
Owensboro, Kentucky, 42303, United States
Lexicon Investigational Site (170)
New Orleans, Louisiana, 70115, United States
Lexicon Investigational Site (190)
New Orleans, Louisiana, 70119, United States
Lexicon Investigational Site (121)
Boston, Massachusetts, 02115, United States
Lexicon Investigational Site (140)
New Bedford, Massachusetts, 02740, United States
Lexicon Investigational Site (225)
Waltham, Massachusetts, 02451, United States
Lexicon Investigational Site (125)
Ann Arbor, Michigan, 48109, United States
Lexicon Investigational Site (108)
Dearborn, Michigan, 48126, United States
Lexicon Investigational Site (139)
Olive Branch, Mississippi, 38654, United States
Lexicon Investigational Site (104)
Hazelwood, Missouri, 63042, United States
Lexicon Investigational Site (174)
Kansas City, Missouri, 64114, United States
Lexicon Investigational Site (184)
Springfield, Missouri, 65807, United States
Lexicon Investigational Site (156)
St Louis, Missouri, 63110, United States
Lexicon Investigational Site (116)
Papillion, Nebraska, 68046, United States
Lexicon Investigational Site (216)
Las Vegas, Nevada, 89106, United States
Lexicon Investigational Site (162)
Las Vegas, Nevada, 89123, United States
Lexicon Investigational Site (142)
New York, New York, 100029, United States
Lexicon Investigational Site (227)
Rochester, New York, 14609, United States
Lexicon Investigational Site (167)
Schenectady, New York, 12304, United States
Lexicon Investigational Site (122)
Westfield, New York, 14787, United States
Lexicon Investigational Site (110)
Williamsville, New York, 14221, United States
Lexicon Investigational Site (200)
Asheville, North Carolina, 28803, United States
Lexicon Investigational Site (209)
Greensboro, North Carolina, 27410, United States
Lexicon Investigational Site (212)
Monroe, North Carolina, 28112, United States
Lexicon Investigational Site (106)
Morehead City, North Carolina, 28557, United States
Lexicon Investigational Site (145)
Winston-Salem, North Carolina, 27103, United States
Lexicon Investigational Site (220)
Beavercreek, Ohio, 45432, United States
Lexicon Investigational Site (168)
Dayton, Ohio, 45424, United States
Lexicon Investigational Site (148)
Norman, Oklahoma, 73069, United States
Lexicon Investigational Site (210)
Oklahoma City, Oklahoma, 73102, United States
Lexicon Investigational Site (187)
Eugene, Oregon, 97404, United States
Lexicon Investigational Site (183)
Charleston, South Carolina, 29406, United States
Lexicon Investigational Site (201)
Columbia, South Carolina, 29205, United States
Lexicon Investigational Site (113)
Greenville, South Carolina, 29607, United States
Lexicon Investigational Site (205)
North Charleston, South Carolina, 29405, United States
Lexicon Investigational Site (202)
Rock Hill, South Carolina, 29730, United States
Lexicon Investigational Site (157)
Summerville, South Carolina, 29486, United States
Lexicon Investigational Site (160)
Memphis, Tennessee, 38119, United States
Lexicon Investigational Site (192)
Austin, Texas, 78759, United States
Lexicon Investigational Site (199)
Baytown, Texas, 77521, United States
Lexicon Investigational Site (193)
Dallas, Texas, 75230, United States
Lexicon Investigational Site (158)
Dallas, Texas, 75231, United States
Lexicon Investigational Site (153)
Euless, Texas, 76040, United States
Lexicon Investigational Site (114)
Flower Mound, Texas, 75028, United States
Lexicon Investigational Site (196)
Harlingen, Texas, 78550, United States
Lexicon Investigational Site (120)
Houston, Texas, 77030, United States
Lexicon Investigational Site (197)
Houston, Texas, 77065, United States
Lexicon Investigational Site (152)
Houston, Texas, 77074, United States
Lexicon Investigational Site (214)
Katy, Texas, 77494, United States
Lexicon Investigational Site (155)
Lewisville, Texas, 75057, United States
Lexicon Investigational Site (223)
Mesquite, Texas, 75150, United States
Lexicon Investigational Site (203)
San Antonio, Texas, 78229, United States
Lexicon Investigational Site (159)
San Antonio, Texas, 78233, United States
Lexicon Investigational Site (221)
San Antonio, Texas, 78240, United States
Lexicon Investigational Site (101)
Salt Lake City, Utah, 84102, United States
Lexicon Investigational Site (219)
Salt Lake City, Utah, 84107, United States
Lexicon Investigational Site (224)
St. George, Utah, 84790, United States
Lexicon Investigational Site (130)
Manassas, Virginia, 20110, United States
Lexicon Investigational Site (165)
Norfolk, Virginia, 23510, United States
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 30, 2023
First Posted
January 12, 2024
Study Start
November 29, 2023
Primary Completion
January 14, 2025
Study Completion
February 24, 2025
Last Updated
October 10, 2025
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will not share